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Abstract: β-Lactam antibiotics are frequently used for treatment of multi-drug resistant microbial infections and the most common mechanism 
of resistance against these antibiotics is bacterial β-lactamase production. Herein, we reported the design, synthesis and in vitro antimicrobial 
activities of some new 2-substituted-5-(2,4-dinitrophenylsulfonamido)benzoxazole derivatives. Compounds TN1, TN2, and TN3 were found to 
be significantly active against E. coli isolate which contains extended spectrum β-lactamase enzyme at the MIC value of 8 µg mL–1 and that is  
4-fold higher than the reference drug ampicillin. We performed molecular docking studies into active site of Escherichia coli TEM-1 β-lactamase 
enzyme in order to predict the protein-ligand interactions. According to the docking results, compounds TN1, TN2, and TN3 showed strong 
interactions between the important active site residues which are responsible for the catalytic mechanism of TEM-1 β-lactamase enzyme and 
a good correlation is found with the experimental data. 
 





HE need for new effective antimicrobial agents to 
prevent the diseases caused by the fastest-growing 
prevalence of multi-drug resistant microbial infections, still 
maintains its importance. For treatment of these infections 
β-lactam antibiotics are frequently used and the most 
common mechanism of resistance against these antibiotics 
is bacterial β-Lactamase production. The Extended 
Spectrum β-lactamase (ESBL) are enzymes that produced 
by Enterobacteriaceae family including Escherichia coli[1–3] 
and the enzymes are derived from broad-spectrum beta 
lactamase TEM-1, TEM-2 or SHV-1 by a limited number of 
mutations.[4] ESBL enzymes hydrolyze the amide bond of β-
lactam ring of penicillins, cephalosporins and related 
antibiotics, thereby inactivating them and often cause 
diseases in clinics and hospitals worldwide.[5] 
 Sulbactam, tazobactam, and clavulanate are known 
as efficient β-lactamase inhibitors however, their efficiency 
is restricted to class A β-lactamases.[4,6,7] Escherichia coli 
TEM-1 β-lactamase enzyme belongs to class A β-lactamases 
and have a broad substrate specificity.[8] In recent years, 
numerous compounds have been reported as β-lactamase 
inhibitors. Eidam et al. synthesized sulfonamide boronic 
acid derivatives and reported their higher β-lactamase 
inhibitory activities.[9] 
 Additionally, a series of phenylethenesulfonamide 
derivatives found to be the potent inhibitors of TEM-1  
β-lactamase enzyme.[10] On the other hand, the 
benzoxazoles are known as an important class of 
heterocyclic compounds exhibiting broad spectrum of 
antimicrobial activities.[11–15] 
 Herein, we designed and synthesized some new 2-
substituted-5-(2,4-dinitrophenylsulfonamido)benzoxazole 
derivatives, which consist of both benzoxazole and 
sulfonamide moieties, and tested their in vitro 
antimicrobial activities. Furthermore we performed 
molecular docking studies into active site of Escherichia coli 
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MATERIALS AND METHODS 
Chemistry 
All of the solvents and chemicals were purchased from 
commercial vendors and were used without purification. 
The melting points were uncorrected and measured on 
Buchi B540. FTIR spectra were obtained on a Agilent 
Technologies Cary 630 FTIR spectrometer. 1H NMR and  
13C NMR spectra were obtained on a VARIAN Mercury  
400 MHz FT spectrometer, chemical shifts were expressed 
as ppm, and coupling constants (J) were expressed as hertz. 
Mass spectra were obtained on a Waters Micromass ZQ 
using the ESI method. Analytical data were obtained on 
elemental analyzer system Leco CHNS-932 CHNS-O analy-
zer and the results (C, H, N, S) were found within ± 0.4 % of 
the calculated amounts. 
 
GENERAL PROCEDURE FOR THE SYNTHESIS OF  
5-(2,4-DINITROPHENYLSULFONAMIDO)BENZOXAZOLE 
DERIVATIVES (TN1-14) 
Firstly, 2-(4-substitutedphenyl)-5-aminobenzoxazole were 
prepared according to literature data.[14–16] Then 0.95 mmol 
pyridine and 0.52 mmol 2,4-dinitrobenzene-sulfonyl 
chloride (d) added to a solution of 0.048 mmol  
2-(4-substitutedphenyl)-5-aminobenzoxazole in 2 mL 
dichloromethane. The reaction mixture was stirred for  
16 hours at the room temperature. At the end of the 
reaction, the solid product was filtered and washed with 
saturated solution of CuSO4 and NaHCO3 in water, then 
recrystallized from ethyl acetate/n-hexan (1 : 4) mixture.[16, 17] 




32 % yield; m.p 223–224 °C; IR max 3337, 3099, 1552, 1477, 
1347, 1326, 1157, 1110 cm−1; 1H NMR (DMSO-d6): d/ppm = 
7.21 (dd, 1H, J = 8.8 Hz, J = 2.4 Hz, H-6), 7.54 (d, 1H, J =  
2.4 Hz, H-4), 7.59-7.65 (m, 3H, H-3', H-4' H-5'), 7.76 (d, 1H, 
J = 8.4 Hz, H-7), 8.16-8.18 (m, 2H, H-2', H-6'), 8.24 (d, 1H,  
J = 9.2 Hz, H-6''), 8.60 (dd, 1H, J = 8.4 Hz, J = 2.4 Hz, H-5''), 
8.89 (d, 1H, J = 2.0 Hz, H-3''), 11.17 (s, 1H, NH); 13C NMR 
(DMSO-d6): d/ppm = 111.62, 113.25, 120.24, 120.46, 
126.04, 127.21, 127.32, 129.34, 131.69, 132.21, 132.77, 
136.00, 142.01, 147.84, 148.08, 150.05, 163.49; ESIMS m/z 
(%) 441.57 (30) [M+H]+; Anal. Calcd. for C19H12N4O7S. 
0.3HOH: C, 51.19; H, 2.85; N, 12.57; S, 7.19. Found: C, 50.98; 




41 % yield; m.p 206–207 °C; IR (KBr) max 3334, 3108, 1539, 
1479, 1347, 1306, 1174, 1094 cm−1; 1H NMR (DMSO-d6): 
d/ppm = 7.22 (dd, 1H, J = 8.8 Hz, J = 2.0 Hz, H-6), 7.54 (d, 
1H, J = 2.4 Hz, H-4), 7.68 (q, 2H, H-3', H-5'), 7.76 (d, 1H, J = 
8.8 Hz, H-7), 8.16 (q, 2H, H-2', H-6'), 8.24 (d, 1H, J = 8.4 Hz, 
H-6''), 8.59 (dd, 1H, J = 8.4 Hz, J = 2.0 Hz, H-5''), 8.89 (d, 1H, 
J = 2.4 Hz, H-3''), 11.09 (s, 1H, NH); 13C NMR (DMSO-d6): 
d/ppm = 111.63, 113.26, 120.24, 120.66, 124.92, 127.21, 
129.07, 129.52, 131.69, 132.90, 135.98, 136.99, 141.94, 
147.84, 148.10, 150.05, 162.57; ESIMS m/z (%) 473.34 (100) 
[M-H]+, 475.30 (40) [M-H+2]+; Anal. Calcd. for 
C19H11ClN4O7S: C, 48.06; H, 2.34; N, 11.80; S, 6.75. Found: 




37 % yield; m.p 207–209 °C. IR max 3341, 3108, 1533, 1480, 
1349, 1144, 1098 cm−1; 1H NMR (DMSO-d6): d/ppm = 7.21 
(dd, 1H, J = 9.2 Hz, J = 2.4 Hz, H-6), 7.44-7.48 (m, 2H, H-3', 
H-5'), 7.53 (d, 1H, J = 2.0, Hz H-4), 7.75 (d, 1H, J = 8.8 Hz, H-
7), 8.20-8.25 (m, 3H, H-2', H-6', H-6''), 8.59 (dd, 1H, J =  
8.4 Hz, J = 2.0 Hz, H-5''), 8.89 (d, 1H, J = 2.0 Hz, H-3''), 11.15 
(s, 1H, NH); 13C NMR (DMSO-d6): d/ppm = 111.61, 113.21, 
116.60 (JC–F = 22.1 Hz), 120.24, 120.44, 122.72 (JC–F = 3.1 Hz), 
127.20, 130.01 (JC–F = 9.1 Hz), 131.68, 132.82, 135.99, 
141.99, 147.84, 148.11, 150.04, 162.68, 164.35 (JC–F = 249.1 
Hz); ESIMS m/z (%) 459.30 (95) [M+H]+; Anal. Calcd. for 
C19H11FN4O7S: C, 49.79; H, 2.42; N, 12.22; S, 6.99. Found: C, 




40 % yield; m.p 219–221 °C; IR max 3332, 3106, 1533, 1474, 
1345, 1172, 1101cm−1; 1H NMR (DMSO-d6): d/ppm = 7.22 
(dd, 1H, J = 8.8 Hz, J = 2.0 Hz, H-6), 7.54 (d, 1H, J = 2.4 Hz,  
H-4), 7.76 (d, 1H, J = 8.8 Hz, H-7), 7.82 (q, 2H, H-3', H-5'), 
8.08 (q, 2H, H-2', H-6'), 8.23 (d, 1H, J = 8.4 Hz, H-6''), 8.59 
(dd, 1H, J = 9.2 Hz, J = 2.4 Hz, H-5''), 8.88 (d, 1H, J = 2.0 Hz, 
H-3''), 11.10 (s, 1H, NH); 13C NMR (DMSO-d6): d/ppm = 
111.69, 113.25, 120.23, 120.68, 125.26, 125.94, 127.19, 
129.17, 131.68, 132.44, 132.94, 135.98, 141.92, 147.82, 
148.07, 150.03, 162.67; ESIMS m/z 517.95 [M-H]+ (100), 
519.14 [M-H+2]+ (100); Anal. Calcd. for C19H11BrN4O7S: C, 
43.95; H, 2.14; N, 10.79; S, 6.17. Found: C, 43.97; H, 2.36; 




42 % yield; m.p 190–191 °C; IR max 3302, 3095-2968, 1539, 
1494, 1345, 1146, 1102 cm−1; 1H NMR (DMSO-d6): d/ppm = 
1.22 (t, 3H, CH3), 2.71 (q, 2H, CH2), 7.19 (dd, 1H, J = 8.4 Hz, 
J = 2.4 Hz, H-6), 7.45 (d, 2H, J = 8.4 Hz, H-3', H-5'), 7.52 (d, 
1H, J = 2.0 Hz, H-4), 7.38 (d, 1H, J = 8.4 Hz, H-7), 8.08 (d, 2H, 
J = 8.4 Hz, H-2', H-6'), 8.24 (d, 1H, J = 8.4 Hz, H-6''), 8.59 (dd, 
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11.14 (s, 1H, NH); 13C NMR (DMSO-d6): d/ppm = 15.09 
(CH3), 28.15 (CH2), 111.49, 113.13, 120.24, 120.25, 123.56, 
127.20, 127.41, 128.76, 131.68, 132.74, 136.04, 142.10, 
147.84, 148.00, 148.54, 150.03, 163.66; ESIMS m/z 469.28 
[M+H]+ (100); Anal. Calcd. for C21H16N4O7S: C, 53.84; H, 





48 % yield; m.p 232–233 °C; IR max 3341, 3106, 1533, 1496, 
1349, 1172, 1101 cm−1;  1H NMR (DMSO-d6): d/ppm = 2.40 
(s, 3H, CH3), 7.18 (dd, 1H, J = 8.8 Hz, J = 2.4 Hz, H-6), 7.41 (d, 
2H, J = 8.0 Hz, H-3', H-5'), 7.50 (d, 1H, J = 2.0 Hz, H-4), 7.72 
(d, 1H, J = 9.2 Hz, H-7), 8.04 (d, 2H, J = 8.0 Hz, H-2', H-6'), 
8.22 (d, 1H, J = 8.8 Hz, H-6''), 8.58 (dd, 1H, J = 8.4 Hz, J =  
2.4 Hz, H-5''), 8.88 (d, 1H, J = 2.4 Hz, H-3''), 11.13 (s, 1H, NH); 
13C NMR (DMSO-d6): d/ppm = 21.14 (CH3), 111.48, 113.13, 
120.23, 120.27, 123.31, 127.20, 127.30, 129.92, 131.69, 
132.72, 136.01, 142.09, 142.49, 147.84, 148.00, 150.03, 
163.67; ESIMS m/z 455.06 [M+H]+ (100); Anal. Calcd. for 
C20H14N4O7S: C, 52.86; H, 3.11; N, 12.33; S, 7.06. Found: C, 




64 % yield; m.p 203–205 °C; IR max 3328, 3106, 1530, 1457, 
1340, 1148, 1101 cm−1; 1H NMR (DMSO-d6): d/ppm = 4.28 
(s, 2H, CH2), 7.10 (dd, 1H, J = 8.4 Hz, J = 2.4 Hz, H-6), 7.24–
7.33 (m, 5H, phenyl'), 7.40 (d, 1H, J = 2.4 Hz, H-4), 7.60 (d, 
1H, J = 8.4 Hz, H-7), 8.16 (d, 1H, J = 8.8 Hz, H-6''), 8.54 (dd, 
1H, J = 8.4 Hz, J = 2.0 Hz, H-5''), 8.84 (d, 1H, J = 2.4 Hz, H-3''), 
11.05 (s, 1H, NH); 13C NMR (DMSO-d6): d/ppm = 34.10 
(CH2), 111.24, 113.16, 119.94, 120.21, 127.09, 127.17, 
128.64, 129.07, 131.64, 132.29, 134.87, 135.99, 141.40, 
147.81, 148.23, 150.00, 166.79; ESIMS m/z 455.00 [M+H]+ 
(100); Anal. Calcd. for C20H14N4O7S: C, 52.86; H, 3.11; N, 




46 % yield; m.p 191–192 °C; IR max 3101, 1537, 1492, 1349, 
1172, 1098 cm−1; 1H NMR (DMSO-d6): d/ppm = 4.30 (s, 2H, 
CH2), 7.11 (dd, 1H, J = 8.4 Hz, J = 2.0 Hz, H-6), 7.35–7.40 (m, 
5H, phenyl', H-4), 7.60 (d, 1H, J = 8.4 Hz, H-7), 8.16 (d, 1H,  
J = 8.8 Hz, H-6''), 8.54 (dd, 1H, J = 8.4 Hz, J = 2.0 Hz, H-5''), 
8.84 (d, 1H, J = 2.0 Hz, H-3''), 11.05 (s, 1H, NH); 13C NMR 
(DMSO-d6): d/ppm = 33.23 (CH2), 111.19, 113.10, 119.92, 
120.14, 127.10, 128.49, 130.99, 131.56, 131.78, 132.24, 
133.80, 135.92, 141.27, 147.74, 148.14, 149.94, 166.39; 
ESIMS m/z 489.30 [M+H]+ (100), 491.07 [M+H+2]+ (36); 
Anal. Calcd. for C20H13ClN4O7S: C, 49.14; H, 2.68; N, 11.46; 
S, 6.56. Found: C, 49.17; H, 2.94; N, 11.71; S, 6.60. 
2-(4-FLUOROBENZYL)-5-(2,4-DINITROPHENYLSULFON-
AMIDO)-BENZOXAZOLE (TN12) 
59 % yield; m.p 178–179 °C; IR max 3185, 3108, 1535, 1466, 
1336, 1170, 1099 cm−1; 1H NMR (DMSO-d6): d/ppm = 4.28 
(s, 2H, CH2), 7.07 (d, 1H, J = 9.2 Hz, H-6), 7.12–7.17 (m, 2H, 
H-2', H-6'), 7.36-7.39 (m, 3H, H-4, H-3', H-5'), 7.56 (d, 1H,  
J = 8.4 Hz, H-7), 8.15 (d, 1H, J = 8.8 Hz, H-6''), 8.52 (dd, 1H,  
J = 8.8 Hz, J = 2.4 Hz, H-5''), 8.81 (s, 1H, H-3''), 11.04 (s, 1H, 
NH); 13C NMR (DMSO-d6): d/ppm = 33.12 (CH2), 111.00, 
112.86, 115.30 (JC-F = 21.8 Hz), 119.96 (JC-F = 5.8 Hz), 126.94, 
130.98, 131.01, 131.05, 131.51, 141.28, 147.76, 147.79, 
149.71, 161.24 (JC-F = 241.7 Hz), 166.44; ESIMS m/z 473.31 
[M+H]+ (100); Anal. Calcd. for C20H13FN4O7S: C, 50.85; H, 





61 % yield; m.p 124–126 °C; IR max 3095-3073, 1537, 1464, 
1364, 1172, 1098 cm−1; 1H NMR (DMSO-d6): d/ppm = 4.29 
(s, 2H, CH2), 7.11 (dd, 1H, J = 8.4 Hz, J = 2.4 Hz, H-6), 7.29–
7.32 (m, 2H, H-2', H-6'), 7.39 (d, 1H, J = 1.6 Hz, H-4), 7.50–
7.53 (m, 2H, H-3', H-5'), 7.60 (d, 1H, J = 8.4 Hz, H-7), 8.16 (d, 
1H, J = 8.8 Hz, H-6''), 8.54 (dd, 1H, J = 8.8 Hz, J = 2.0 Hz, H-
5''), 8.84 (d, 1H, J = 1.6 Hz, H-3''), 11.04 (s, 1H, NH); 13C NMR 
(DMSO-d6): d/ppm = 33.30 (CH2), 111.19, 113.09, 119.92, 
120.14, 120.26, 127.10, 131.36, 131.43, 131.56, 132.25, 
134.21, 135.92, 141.26, 147.74, 148.14, 149.94, 166.32; 
ESIMS m/z 533.24 [M+H]+ (100), 535.06 [M+H+2]+ (100); 
Anal. Calcd. for C20H13BrN4O7S: C, 45.04; H, 2.46; N, 10.51; 




31 % yield; m.p 192–193 °C; IR max  31110-3037, 1537, 
1472, 1349, 1172, 1105 cm−1; 1H NMR (DMSO-d6): d/ppm = 
2.24 (s, 3H, CH3), 4.22 (s, 2H, CH2), 7.08-7.12 (m, 3H, H-6, H-
3', H-5'), 7.20 (d, 2H, J = 8.0 Hz, H-2', H-6'), 7.39 (d, 1H,  
J = 2.0 Hz, H-4), 7.59 (d, 1H, J = 8.4 Hz, H-7), 8.16 (d, 1H,  
J = 8.8 Hz, H-6''), 8.54 (dd, 1H, J = 8.8 Hz, J = 2.0 Hz, H-5''), 
8.83 (d, 1H, J = 2.4 Hz, H-3''), 11.04 (s, 1H, NH); 13C NMR 
(DMSO-d6): d/ppm = 20.52 (CH3), 33.64 (CH2), 111.13, 
113.07, 119.83, 120.13, 127.08, 128.85, 129.11, 131.57, 
131.71, 132.19, 135.93, 136.16, 141.34, 147.74, 148.15, 
149.93, 166.88; ESIMS m/z 469.32 [M+H]+ (100); Anal. 
Calcd. for C21H16N4O7S: C, 53.84; H, 3.44; N, 11.96; S, 6.84. 
Found: C, 53.72; H, 3.53; N, 11.97; S, 6.81. 
Antimicrobial Evaluation 
Standard strains of E. coli ATCC 25922, E. coli isolate (ESBL: 
Extended spectrum β-lactamase, resistant to all β-lactam 
antibiotics), Pseudomonas aeruginosa ATCC 27853, P. 
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baumannii ATCC 17978, Acinetobacter baumannii isolate 
(resistant to ciprofloxacin), Staphylococcus aureus ATCC 
29213, S. aureus isolate [MRSA (meticillin resistant 
S.aureus)], Enterococcus faecalis ATCC 29212, E. faecalis 
isolate (resistant to vancomycin) and Candida albicans 
ATCC 10231 were used in the study. 
Microdilution Method 
Mueller Hinton Agar (MHA), Cation Adjusted Mueller 
Hinton Broth (CAMHB), Sabouraud Dextrose Agar (SDA), 
Sabouraud Liquid Medium (SLM) and RPMI-1640 medium 
with L-glutamine (Sigma) buffered with MOPS (pH7) media 
were used during the study. Microdilution method was 
used to determine the susceptibilities of the microorganisms 
according to the guidelines of Clinical and Laboratory 
Standards Institute (CLSI) M100-S25[18] and M27-A3[19] 
standards. For bacteria 100 µL of CAMHB for Candida RPMI-
1640 medium with L-glutamine buffered with MOPS (pH7) 
were added to each well of the microplates. 
 McFarland 0.5 turbidity standard was used to 
standardize the inoculum density of the microorganisms. 
Saline suspension of 16–20 hours grown pure colonies of 
bacteria or fungi were adjusted to achieve McFarland 
turbidity. The inoculum concentrations resulted in 
suspensions containing 1–2 × 108 CFU mL–1 bacteria. 
Bacterial inoculum suspensions were diluted 1 : 20 to yield 
1 × 106 CFU mL–1 and the final suspension in the wells of the 
microplate was 105 CFU mL–1. Inoculum suspension of 
Candida albicans was diluted 1: 100 and 1: 20 respectively 
and 2.5 × 103 CFU mL–1 were inoculated to the twofold-
diluted solution of the compounds. 
 Standard powders of ampicillin (Sigma), gentamycin 
(Sigma), ciprofloxacin (Sigma), meropenem (Sigma) and 
fluconazole (Sigma) were used as control. Stock solutions of 
the tested compounds were dissolved in DMSO (Merck). 
Standard antibiotic solutions were dissolved in appropriate 
solvents recommended by CLSI guidelines.[18] 
 
Antibiotics Diluent Solvent 
ampicillin 0.1 mol dm3 pH 6 PBS 0.1 mol dm3 pH 8 PBS 
gentamycin distilled water distilled water 
ciprofloxacin distilled water distilled water 
fluconazole 1 : 9 water : ethanol distilled water 
 
 A hundred microliters of the stock solutions of 
standard drugs and the tested compounds were added to 
the first wells of the microplates and diluted two-fold in the 
wells of the microplates. The solution of the synthesized 
compounds and standard drugs were prepared at 1024, 
512, 256, 128, 64, 32, 16, 8 µg mL–1 and 16, 8, 4, 2, 1, 0.5, 
0.25, 0.125 µg mL–1 concentrations, respectively. All 
solvents and diluents, pure media and pure 
microorganisms were used in control wells. 
 Finally, a 10 µL microorganism inoculums were 
added to each well of the microplates. Bacteria were 
incubated for 16–20 hours at 37 °C and fungi were 
incubated for 24–48 hours at 35 °C. After incubation, the 
lowest concentration of the compounds that completely 
inhibits macroscopic growth was determined and 
reported as minimum inhibitory concentrations (MICs). 
 
Molecular Docking 
The crystal structure of the TEM-1 β-lactamase enzyme 
of E. coli was selected for molecular docking studies 
(PDB ID: 1ERQ).[20] Protein and ligands were prepared by 
using Accelrys Discovery Studio 3.5 software.[21] Target 
protein, TEM-1 β-lactamase enzyme was taken, 
hydrogens were added the ligand was extracted, and 
optimized using the all atom CHARMm forcefield and the 
Adopted Basis set Newton Raphson method until the 
root mean deviation (RMS) gradient was < 0.05 kcal / 
mol / Å2. By using the binding site module, minimized 
protein was defined as the receptor. The binding site 
was defined from the cavity finding method and 
modified that contain all of the important active site 
residues of the β-lactamase enzyme. Binding sphere 
(40.78, 36.48, 31.78, 8.27) was selected from the active 
site. The most active compounds against E. coli isolate 
(TN1, TN2, TN3) and the boronate inhibitor that is the 
ligand of 1ERQ.pdb crystal structure were sketched, all 
atom CHARMm forcefield parameterization was 
assigned and then minimized using the ABNR method as 
described above. Conformational searches of the ligands 
were performed using a simulated annealing molecular 
dynamics approach. The ligands were heated to a 
temperature of 700 K and then annealed to 200 K. 
CDOCKER method was performed by using Discovery 
Studio 3.5.[22] TEM-1 β-lactamase enzyme was held rigid 
but the ligands were allowed to be flexible during 
refinement. At first the methodology was validated by 
docking of boronate inhibitor. The docked position of 
boronate inhibitor overlaps well with an RMSD of 1.3 Å 
with the crystal structure position. Afterwards 
molecular docking studies were performed on the 
compounds TN1, TN2, TN3. All docked poses were 
scored by applying Analyze Ligand Poses subprotocol 
and binding energies were calculated by using in situ 
ligand minimization step (ABNR method) and using 
implicit solvent model (GBMV) in Discovery Studio 3.5 
software. The lowest binding energy was taken as the 
best-docked conformation of the compounds for the 
macromolecule. The pictures were taken by using 
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RESULTS AND DISCUSSION 
Chemistry 
In this study, 2-(4-substitutedphenyl/benzyl)-5-(2,4-
dinitrophenylsulfonamido)benzoxazole derivatives (TN1–
TN14) were synthesized for the first time. At first step,  
5-amino-2-substitutedbenzoxazoles were obtained.[14–16] 
Then 2,4-dinitrobenzenesulfonyl chloride and 5-amino-2-
substitutedbenzoxazole derivatives were treated in 
pyridine and dichloromethane to obtain 5-(2,4-
dinitrophenyl-sulfonamido)benzoxazole derivatives (TN1–
TN14) (Scheme 1).[16,17] Synthesized structures were 
characterized by 1H NMR, 13C NMR, Mass Spectra and 
Elemental Analysis and the results are in agreement with 
the proposed structures. According to the 1H NMR spectra 
of the compounds the signals of NH (SO2NH) proton of the 
compounds was observed at 11.05–11.17 ppm. Aromatic 
CH3 and benzylic CH2 protons were appeared at 2.24– 
2.40 ppm and 2.71–4.30 ppm, respectively. All the aromatic 
protons were observed at 7.07–8.39 ppm. 13C NMR spectra 
were appropriate to formulas of the synthesized 
compounds and Mass spectra showed M+ + H peaks in 
accordance with their formulas. Additionally, elemental 
analyses results of C, H, N, S were found within ± 0.4 % of 
the calculated amounts. 
 
Scheme 1. Synthetic pathway of 5-(2,4-
dinitrophenylsulfon-amido) benzoxazole (TN1–14) 
derivatives. Reagents and conditions: Pyridine and 
dichloromethane, RT, 16 h. 
 






Code X R E.c. E.c.* P.a. P.a.* A.b A.b* S.a. S.a.* E.f. E.f.* C.a. 
TN1 – H 128 8 256 128 128 128 256 256 128 128 128 
TN2 – Cl 128 8 256 128 128 128 256 256 32 16 128 
TN3 – F 128 8 256 128 128 128 256 256 32 128 128 
TN4 – Br 128 128 256 128 128 128 256 512 128 128 128 
TN5 – C2H5 128 128 256 128 128 128 16 16 32 64 128 
TN6 – CH3 128 256 256 128 128 128 256 256 256 256 128 
TN10 CH2 H 128 16 256 128 128 128 16 16 64 32 128 
TN11 CH2 Cl 128 128 256 128 128 128 16 16 64 128 128 
TN12 CH2 F 128 32 256 128 128 64 16 256 64 64 128 
TN13 CH2 Br 128 128 256 128 128 128 16 16 128 64 128 
TN14 CH2 CH3 128 128 128 128 128 64 32 32 64 128 128 
Ciprofloxacin < 0.125 1 0.5 0.25 > 32 > 32 0.5 > 32 1 > 32 – 
Ampicillin 4 > 32 – – – – 2 > 32 2 8 – 
Meropenem < 0.125 0.125 1 1 8 > 32 < 0.125 > 32 8 32 – 
Gentamycin 1 4 1 2 > 32 32 1 > 32 16 > 32 – 
Fluconazole – – – – – – – – – – 1 
(Abbreviations: E.c.:Escherichia coli ATCC 25922; E.c.*: E. coli isolate; P.a.: Pseudomonas aeruginosa ATCC 25758; P.a.*: P. aeruginosa isolate; A.b.: Acinetobacter 
baumannii ATCC 17978; A.b.*: Acinetobacter isolate; S.a.: Staphylococcus aureus ATCC 29213; S.a.*: S. aureus isolate; E.f.: Enterococcus faecalis ATCC 29212; E.f.*: 
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In vitro Antimicrobial Evaluation 
All of the synthesized 2-(4-substitutedphenyl/benzyl)-5-
(2,4-dinitrophenylsulfonamido)benzoxazoles (TN1–TN14), 
were tested for their in vitro antimicrobial activities against 
Escherichia coli ATCC 25922, E. coli isolate (ESBL), 
Pseudomonas aeruginosa ATCC 27853, P. aeruginosa 
isolate (resistant to ciprofloxacin), Acinetobacter 
baumannii ATCC 17978, A. baumannii isolate (resistant to 
ciprofloxacin) as Gram-negative bacteria, Staphylococcus 
aureus ATCC 29213, S. aureus isolate [MRSA (meticillin 
resistant S. aureus)], Enterococcus faecalis ATCC 29212, E. 
faecalis isolate (resistant to vancomycin) as Gram-positive 
bacteria and Candida albicans ATCC 10231 as fungus. The 
standard drugs, ciprofloxacin, ampicillin, meropenem, 
gentamycin for antibacterial activity, and fluconazole for 
antifungal activity were screened under identical 
conditions for quality control and comparison. 
Microdilution method was used for determination of 
Minimum Inhibitory Concentration (MIC) values as seen in 
Table 1. 
 In vitro biological results demonstrated that all of the 
synthesized compounds showed a wide spectrum of 
activity against the tested microorganisms at MIC values 
between 8 and 512 µg mL–1. Most of the tested compounds 
showed significant antibacterial activities against S. aureus, 
E. faecalis and their drug resistant isolates. Compounds 
TN5, TN10, TN11 and TN13 showed high antibacterial 
activity against drug resistant isolate of S. aureus with the 
MIC value of 16 µg mL–1 and they were found to be 2-fold 
more effective than all of the reference drugs. Compounds 
TN2 and TN10 showed better activity than the reference 
drugs ciprofloxacin, meropenem and gentamycin against 
drug resistant isolate of E. faecalis with the MIC values of 
16-32 µg mL–1. 
 Moreover, compounds TN1, TN2 and TN3 showed 
significant antibacterial activity against E. coli isolate with 
the MIC value of 8 µg mL–1 and that is 4-fold higher than the 
reference drug ampicillin. According to obtained data, CH2 
bridge which placed on the 2nd position of benzoxazole ring 
seems to decrease the activity against E. coli isolate. 
Molecular Docking Studies 
In this study, compounds TN1, TN2, and TN3 were found to 
be significantly active at the MIC value of 8 µg mL–1 against 
E. coli isolate which contains extended spectrum β-
lactamase enzyme. Molecular docking studies were 
performed on these compounds in order to understand the 
interactions between the compounds and TEM-1 β-
lactamase enzyme by using CDOCKER method.[20,21] 
 TEM-1 is the most common β-lactamase in Gram-
negative bacteria, belonging to Class A beta-lactamases 2b 
group and ampicillin resistance is highly associated with the 
production of TEM-1 in E. Coli.[4] The active site of TEM-1 β-
lactamase enzyme including the residues: Ser70, Lys73, 
Ser130, Asn132, Glu166, Lys234, Ala237. It is reported that 
all of these residues play important roles in catalytic 
mechanism of the β-lactamase enzyme. Ser70 covalently 
bound to β-lactam ring as an acyl-enzyme intermediate and 
Lys73 acts as a general base in abstracting a proton from 
Ser70 and transferring it to the thiazolidine ring of β-lactam 
antibiotic via Ser130.[23,24] 
 According to the docking results, boronate inhibitor 
revealed H bonds with Ser70, Ser130, Asn170, Ala237 and 
Arg243; revealed pi-alkyl interaction with Tyr105 that are 
in accordance with the X-ray structure of 1ERQ.pdb. One 
of the most active compounds TN1 revealed H bonds with 
Ser130 and Arg243; revealed pi-pi stacking with Tyr105,  
pi-donor interaction with Asn132, pi-alkyl interaction with 
Val 216 and Ala237, pi-sulfur interaction with Met270 
(Figure 1b). TN2 revealed halogen bond with Asn132; 
revealed pi-alkyl interactions with Pro219, Ala237 and 
Met270 (Figure 1c). TN3 revealed H bond with Ser70; 
revealed pi-pi stacking with Tyr105, pi-alkyl interaction 
with Val216 and Ala237, pi-sulfur interaction with Met270 
(Figure 1d). Binding energies of the compounds TN1, TN2, 
TN3 and boronate inhibitor are –3.60, –2.85, –5.43 and  
–11.38, respectively (Table 2). In vitro biological results 
demonstrated that TN1, TN2 and TN3 exhibited promising 
antimicrobial activity against E. coli isolate and the 
docking results were also correlated with the 
microbiological data. 
 




 kcal mol–1 
Interacted Residues in  4 Å 
TN1 –3.60 
Ser70, Lys73, Tyr105,(a) Ser130 (2.98 Å), 
Asn132,(c) Glu166, Asn170, Val216,(b) 
Ser235, Gly236, Ala237,(b) Gly238, 
Arg243 (2.04 Å), Met270(d)  
TN2 –2,85 
Ser70, Lys73, Tyr105, Ser130, Asn132(x) 
(3.06 Å), Asn170, Lys215, Val216, Gly218, 
Pro219,(b) Ala237,(b) Gly238, Met270(b) 
TN3 –5.43 
Ser70 (2.31 Å), Lys73, Tyr105,(a) Met129, 
Ser130, Asn132, Glu166, Asn170, Lys215, 





Met69, Ser70 (2.10, 2.29 Å), Lys73, 
Tyr105,(b) Ser130 (2.00, 2.11 Å), Asn132, 
Asn170 (1.80 Å), Val216, Lys234, Ser235, 
Gly236, Ala237 (2.11, 2.64 Å), Gly238, 
Glu239, Arg243 (1.82 Å), H2O510 (water 
mediated H-bonds with Val216 (1.96 Å) 
and Arg243 (1.86 Å) 
Bold: H-bonds; 
(a) pi-pi interactions. 
(b) pi-alkyl interactions. 
(c) pi-donor interactions. 
(d) pi-sulfur interactions. 




 T. ERTAN-BOLELLI et al.: Synthesis, Antimicrobial Activities of New Sulfonamidobenzoxazoles … 73 
 





Herein, we designed and synthesized some new 2-
substituted-5-(2,4-dinitrophenylsulfonamido)benzoxazoles 
and tested their in vitro antimicrobial activities. All of the 
tested compounds showed significant activity against the 
tested microorganisms especially extended spectrum  
β-lactamase containing E. coli isolate. Compounds TN1, TN2, 
and TN3 were found to be significantly active with the MIC 
value of 8 µg mL–1 against the extended spectrum  
β-lactamase containing E. coli isolate, which was resistant to 
all β-lactam antibiotics. In order to predict the protein-ligand 
interactions we performed molecular docking studies into 
active site of E. coli TEM-1 β-lactamase enzyme. According to 
the docking results, compounds TN1, TN2, and TN3 showed 
strong interactions between the important active site 
residues which are responsible for the catalytic mechanism 
of TEM-1 β-lactamase enzyme, such as Ser70, Ser130, and 
Asn132. A good correlation was noticed between the docking 
scores and the microbiological data. It can be concluded that 
these compounds could show their activity by inhibiting the 
β-lactamase enzyme. The compounds obtained from this 
study can be useful in designing of new potent β-lactamase 
inhibitors by using them as lead compounds. 
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